Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor

Endocrine-Related Cancer

Volumn 16, Issue 1, 2009, Pages 155-169

  Malinowska, Kamilla ^a   Neuwirt, Hannes ^a   Cavarretta, Ilaria T ^a   Bektic, Jasmin ^a   Steiner, Hannes ^a   Dietrich, Hermann ^a   Moser, Patrizia L ^b   Fuchs, Dietmar ^a   Hobisch, Alfred ^c   Culig, Zoran ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

^c General Hospital Feldkirch   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANDROGEN RECEPTOR; BICALUTAMIDE; INTERLEUKIN 6; STAT3 PROTEIN; ANILIDE; ANTINEOPLASTIC AGENT; IL6 PROTEIN, HUMAN; INTERLEUKIN 6 RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NITRILE; STAT3 PROTEIN, HUMAN; TOLUENESULFONIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL DIVISION; DRUG EFFECT; GENETICS; METABOLISM; NUDE MOUSE; ORCHIECTOMY; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANILIDES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL LINE, TUMOR; HUMANS; INTERLEUKIN-6; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM TRANSPLANTATION; NITRILES; ORCHIECTOMY; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, INTERLEUKIN-6; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TOSYL COMPOUNDS;

EID: 65549130575     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-08-0174     Document Type: Article

References (64)

1. Bakin RE, Gioeli D, Sikes RA, Bissonette EA & Weber MJ 2003 Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Research 63 1981-1989.
2. Bellezza I, Neuwirt H, Nemes C, Cavarretta IT, Puhr M, Steiner H, Minelli A, Bartsch G, Offner F, Hobisch A et al. 2006 Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer. American Journal of Pathology 169 2199-2208.
3. Bellido T, Jilka RL, Boyce BF, Girasole G, Broxmeyer H, Dalrymple SA, Murray R & Manolagas SC 1995 Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. Journal of Clinical Investigation 95 2886-2895.
4. Bradford M 1978 A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Analytical Biochemistry 72 248-254.
5. Buchanan G, Greenberg NM, Scher HI, Harris JM, Marshall VR & Tilley WD 2001 Collocation of androgen receptor gene mutations in prostate cancer. Clinical Cancer Research 7 1273-1281.
6. Cavarretta IT, Neuwirt H, Untergasser G, Moser PL, Zaki MH, Steiner H, Rumpold H, Fuchs D, Hobisch A, Nemeth JA et al. 2007 The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene 26 2822-2832.
7. Chen CD & Sawyers CL 2002 NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Molecular and Cellular Biology 22 2862-2870.
8. Chen RH, Chang MC, Su YH, Tsai YT & Kuo ML 1999a Interleukin-6 inhibits transforming growth factor-beta-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways. Journal of Biological Chemistry 274 23013-23019.
9. Chen T, Cho RW, Stork PJ & Weber MJ 1999b Elevation of cyclic adenosine 3′5′-monophosphate potentiates activation of mitogen-activated protein kinase by growth factors in LNCaP prostate cancer cells. Cancer Research 59 213-218.
10. Chen T, Wang LH & Farrar WL 2000 Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Research 60 2132-2135.
11. Chen S-C, Chang YL, Ling Wang D & Cheng J-J 2006 Herbal remedy magnolol suppresses IL-6 induced STAT3 activation and gene expression in endothelial cells. British Journal of Pharmacology 148 226-232.
12. Chung TD, Yu JJ, Spiotto MT, Bartkowski M & Simons JW 1999 Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 38 199-207.
13. Craft N, Shostak Y, Carey M & Sawyers CL 1999 A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Medicine 5 280-285.
14. Culig Z, Hobisch A, Cronauer MV, Cato AC, Hittmair A, Radmayr C, Eberle J, Bartsch G & Klocker H 1993 Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Molecular Endocrinology 7 1541-1550.
15. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G & Klocker H 1994 Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Research 54 5474-5478.
16. Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K et al. 1999 Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system. British Journal of Cancer 81 242-251.
17. Culig Z, Steiner H, Bartsch G & Hobisch A 2005a Interleukin-6 regulation of prostate cancer cell growth. Journal of Cellular Biochemistry 95 497-505.
18. Culig Z, Steiner H, Bartsch G & Hobisch A 2005b Mechanisms of endocrine therapy-reponsive and -unresponsive prostate tumours. Endocrine-Related Cancer 12 229-244.
19. Daeipour M, Kumar G, Amaral MC & Nel AE 1993 Recombinant IL-6 activates p42 and p44 mitogen-activated protein kinases in the IL-6 responsive B cell line, AF-10. Journal of Immunology 150 4743-4753.
20. Debes JD, Schmidt LJ, Huang H & Tindall DJ 2002 p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Research 62 5632-5636.
21. Degeorges A, Tatoud R, Fauvel-Lafeve F, Podgorniak MP, Millot G, de Cremoux P & Calvo F 1996 Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6. International Journal of Cancer 68 207-214.
22. Desai SJ, Ma AH, Tepper CG, Chen HW & Kung HJ 2006 Inappropriate activation of the androgen receptor by nonsteroids: involvement of the Src kinase pathway and its therapeutic implications. Cancer Research 66 10449-10459.
23. Dong JT 2006 Prevalent mutations in prostate cancer. Journal of Cellular Biochemistry 97 433-447.
24. Ernst M, Oates A & Dunn AR 1996 Gp130-mediated signal transduction in embryonic stem cells involves activation of Jak and Ras/ mitogen-activated protein kinase pathways. Journal of Biological Chemistry 271 30136-30143.
25. Franco OE, Onishi T, Yamakawa K, Arima K, Yanagawa M, Sugimura Y & Kawamura J 2003 Mitogen-activated protein kinase pathway is involved in androgen-independent PSA gene expression in LNCaP cells. Prostate 56 319-325.
26. Godoy-Tundidor S, Cavarretta IT, Fuchs D, Fiechtl M, Steiner H, Friedbichler K, Bartsch G, Hobisch A & Culig Z 2005 Interleukin-6 and oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Prostate 64 209-216.
27. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M & Miyamoto M 2003 Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Research 63 149-153.
28. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Neven G & Schaper F 2003 Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochemical Journal 374 1-20.
29. Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H & Culig Z 1998 Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Research 58 4640-4645.
30. Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H & Culig Z 2001 Prostate cancer cells (LNCaP) generated after long-term interleukin-6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clinical Cancer Research 7 2941-2948.
31. Horiguchi A, Oya M, Marumo K & Murai M 2002 STAT3, but not ERKs, mediates the IL-6-induced proliferation of renal cancer cells. Kidney International 61 926-938.
32. Huggins C, Stevens RE & Hodges CV 1941 Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Archives of Surgery 43 209-223.
33. Keller ET, Chang C & Ershler WB 1996 Inhibition of NFkappaB activity through maintenance of IkappaBalpha levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter. Journal of Biological Chemistry 271 26267-26275.
34. Kitamura H, Okamoto S, Shimamoto Y, Morimatsu M, Terao A & Saito M 1998 Central IL-1 differentially regulates peripheral IL-6 and TNF synthesis. Cellular and Molecular Life Sciences 54 282-287.
35. Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun A, Witte ON et al. 1997 Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nature Medicine 3 402-408.
36. Kohase M, Henriksen-DeStefano D, May LT, Vilcek J & Sehgal PB 1986 Induction of beta 2-interferon by tumor necrosis factor: a homeostatic mechanism in the control of cell proliferation. Cell 45 659-666.
37. Kopantzev Y, Heller M, Swaminathan N & Rudikoff S 2002 IL-6 mediated activation of STAT3 bypasses Janus kinases in terminally differentiated B lineage cells. Oncogene 21 6791-6800.
38. Kreis S, Munz GA, Haan S, Heinrich PC & Behrmann I 2007 Cell density dependent increase of constitutive signal transducers and activators of transcription 3 activity in melanoma cells is mediated by Janus kinases. Molecular Cancer Research 5 1331-1341.
39. Lee LF, Guan J, Qiu Y & Kung HJ 2001 Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Molecular and Cellular Biology 21 8385-8397.
40. Li ZG, Danis VA & Brooks PM 1993 Effect of gonadal steroids on the production of IL-1 and IL-6 by blood mononuclear cells in vitro. Clinical and Experimental Rheumatology 11 157-162.
41. Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L, Zhao Y, DiConcini D, Puxeddu E, Esen A et al. 2000 Androgen receptor mutations in prostate cancer. Cancer Research 60 944-949.
42. Moran DM, Mattocks MA, Cahill PA, Koniaris LG & McKillop IH 2008 Interleukin-6 mediates G(0)/G(1) arrest in hepatocellular carcinoma through a STAT3-dependent pathway. Journal of Surgical Research 147 23-33.
43. Mori S, Murakami-Mori K & Bonavida B 1999 Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. Biochemical and Biophysical Research Communications 257 609-614.
44. Nakafuku M, Satoh T & Kaziro Y 1992 Differentiation factors, including nerve growth factor, fibroblast growth factor, and interleukin-6, induce an accumulation of an active Ras. GTP complex in rat pheochromocytoma PC12 cells. Journal of Biological Chemistry 267 19448-19454.
45. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H & Murai M 2000 Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clinical Cancer Research 6 2702-2706.
46. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, von Eschenbach AC et al. 1997 Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clinical Cancer Research 3 2493-2500.
47. Nazareth LV & Weigel NL 1996 Activation of the human androgen receptor through a protein kinase A signaling pathway. Journal of Biological Chemistry 271 19900-19907.
48. Papatsoris AG, Karamouzis MV & Papavassiliou AG 2007 The power and promise of 'rewiring' the mitogen-activated protein kinase network in prostate cancer therapeutics. Molecular Cancer Therapeutics 6 811-819.
49. Putz T, Culig Z, Eder IE, Nessler-Menardi C, Bartsch G, Grunicke H, Überall F & Klocker H 1999 Epidermal growth factor receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Research 59 227-233.
50. Seaton A, Scullin P, Maxwell PJ, Wilson C, Pettigrew J, Gallagher R, O'Sullivan JM, Johnston PG & Waugh DJ 2008 Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis 29 1148-1156.
51. Smith PC & Keller ET 2001 Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate 48 47-53.
52. Sortino MA, Condorelli F, Vancheri C, Chiarenza A, Bernardini R, Consoli U & Canonico PL 2000 Mitogenic effect of nerve growth factor (NGF) in LNCaP prostate adenocarcinoma cells: role of the high- and low-affinity NGF receptors. Molecular Endocrinology 14 124-136.
53. Spiotto MT & Chung TD 2000 STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. Prostate 42 88-98.
54. Steiner H, Godoy-Tundidor S, Rogatsch H, Berger AP, Fuchs D, Comuzzi B, Bartsch G, Hobisch A & Culig Z 2003 Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. American Journal of Pathology 162 655-663.
55. Steiner H, Cavarretta IT, Moser PL, Berger AP, Bektic J, Dietrich H, Zaki MH, Nakada M, Hobisch A, Nemeth JA et al. 2006 Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328. Prostate 66 1744-1752.
56. Suzuki H, Sato N, Watabe Y, Masai M, Seino S & Shimazaki J 1993 Androgen receptor gene mutations in human prostate cancer. Journal of Steroid Biochemistry and Molecular Biology 46 759-765.
57. Ueda T, Bruchovsky N & Sadar MD 2002a Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. Journal of Biological Chemistry 277 7076-7085.
58. Ueda T, Mawji NR, Bruchovsky N & Sadar MD 2002b Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. Journal of Biological Chemistry 277 38087-38094.
59. Wallner L, Dai J, Escara-Wilke J, Zhang J, Yao Z, Lu Y, Trikha M, Nemeth JA, Zaki MH & Keller ET 2006 Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Research 66 3087-3095.
60. Wang Q, Horiatis D & Pinski J 2004 Interleukin-6 inhibits the growth of prostate cancer xenografts in mice by the process of neuroendocrine differentiation. International Journal of Cancer 111 508-513.
61. Wang G, Jones SJ, Marra MA & Sadar MD 2006 Identification of genes targeted by the androgen and PKA signaling pathways in prostate cancer cells. Oncogene 25 7311-7323.
62. Wegiel B, Bjartell A, Culig Z & Persson JL 2008 Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. International Journal of Cancer 122 1521-1529.
63. Yang L, Wang L, Lin HK, Kan PY, Xie S, Tsai MY, Wang PH, Chen YT & Chang C 2003 Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells. Biochemical and Biophysical Research Communications 305 462-469.
64. Zhao XY, Boyle B, Krishnan AV, Navone NM, Peehl DM & Feldman D 1999 Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. Journal of Urology 162 2192-2199.